Kumar, Rashmi
https://orcid.org/0000-0001-6442-8434
Mayo Clinic
National Comprehensive Cancer Network
Citations 2
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E
Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available
The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Bailey, Janet E., Burstein, Harold J. , Chen, Nan , Chew, Helen K. , Dang, Chau T. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Lyons, Janice A., McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Santa‐Maria, Cesar A. , Schneider, Bryan P. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wei, Mei , Wisinski, Kari B. , Yellala, Amulya, Schonfeld, Ryan, Kumar, Rashmi , Telli, Melinda L , Abramson, Vandana G. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Soliman, Hatem Hussein , Yeung, Kay T. , Young, Jessica S.
Journal of the National Comprehensive Cancer Network | November 10, 2025 | Volume: 23 | Issue: 11 | Pages: 426-436
The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.